Spore-Based Probiotic Composition for Reduction of Dietary Endotoxemia and Related Methods
A method of treating metabolic endotoxemia comprising identifying a subject having post-prandial dietary endotoxemia and administering an effective amount of a spore-based probiotic. While any spore-based probiotic may be used, the probiotic supplement may comprise Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans, Bacillus licheniformis , and Bacillus clausii . One or more of a level of blood endotoxin, triglyceride, post-prandial insulin, post-prandial ghrelin level, MCP-1, GM-CSF, IL-12p70, IL-13, IL-1beta, IL-4, IL-5, IL-6, IL-7, IL-8, and TNF-α is observed as being lower after spore-based probiotic supplementation when compared to placebo. At least one of post-prandial leptin and IL-10 is observed as being higher after spore-based probiotic supplementation when compared to placebo.
1 . A method of treating metabolic endotoxemia comprising:
identifying a subject having metabolic endotoxemia; and
administering an effective amount of a spore-based probiotic.
2 . The method of claim 1 , wherein the spore-based probiotic comprises spores selected from the group of genus consisting of: Lactobacillus, Bifidobacterium, Lactococcus, Propionibacterium, Bacillus, Enterococcus, Escherichia, Streptococcus, Pediococcus, Saccharomyce.
3 . The method of claim 1 , wherein the spore-based probiotic comprises spores selected from the group consisting of Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans, Bacillus licheniformis , and Bacillus clausii.
4 . The method of claim 1 , further comprising reducing at least one of a post-prandial insulin level, a post-prandial ghrelin level, and an MCP-1 level.
5 . The method of claim 1 , further comprising reducing a level of at least one of GM-CSF, IL-12p70, IL-13, IL-1beta, IL-4, IL-5, IL-6, IL-7, IL-8, and TNF-α.
6 . The method of claim 1 further comprising increasing at least one of a post-prandial leptin level and an IL-10 level.
7 . The method of claim 1 , wherein the spore-based probiotic comprises spores having a survival rate between about 75% and 99% after exposure to gastric acid.
8 . The method of claim 1 , wherein the spore-based probiotic comprises spores having a survival rate greater than about 90% after exposure to gastric acid.
9 . The method of claim 1 , wherein the spore-based probiotic is in at least one of a liquid form, a pill form and a food product form.
10 . The method of claim 1 , wherein the subject experiences at least one of a reduction in triglyceride and a post-prandial reduction of an endotoxin after administration of the effective amount of the spore-based probiotic.
11 . The method of claim 10 , wherein the endotoxin comprises lipopolysaccharide (LPS).
12 . A method of reducing a blood endotoxin level comprising:
identifying a subject having an increased post-prandial level of a blood endotoxin; and
administering an effective amount of a spore-based probiotic.
13 . The method of claim 12 , wherein the spore-based probiotic comprises spores selected from the group of genus consisting of Lactobacillus, Bifidobacterium, Lactococcus, Propionibacterium, Bacillus, Enterococcus, Escherichia, Streptococcus, Pediococcus, Saccharomyce.
14 . The method of claim 12 , wherein the spore-based probiotic comprises spores selected from the group consisting of Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans, Bacillus licheniformis , and Bacillus clausii.
15 . The method of claim 12 , wherein the spore-based probiotic comprises spores having a survival rate between about 75% and 99% after exposure to gastric acid.
16 . The method of claim 12 , wherein the spore-based probiotic comprises spores having a survival rate greater than about 90% after exposure to gastric acid.
17 . The method of claim 12 , further comprising reducing at least one of an endotoxin level and a triglyceride level of the subject after administration of the effective amount of the spore-based probiotic.
18 . The method of claim 17 , wherein the endotoxin comprises lipopolysaccharide (LPS).
19 . The method of claim 12 , further comprising reducing at least one of a post-prandial insulin level, a post-prandial ghrelin level, and an MCP-1 level after administration of the effective amount of the spore-based probiotic.
20 . The method of claim 12 , further comprising reducing a level of at least one of GM-CSF, IL-12p70, IL-13, IL-1beta, IL-4, IL-5, IL-6, IL-7, IL-8, and TNF-α after administration of the effective amount of the spore-based probiotic.
21 . The method of claim 12 , further comprising increasing at least one of a post-prandial leptin level and an IL-10 level after administration of the effective amount of the spore-based probiotic.
22 . The method of claim 12 , wherein the spore-based probiotic is in at least one of a liquid form, a pill form, and a food product form.